Tumor Infiltrating Lymphocytes (TIL) is under clinical development by Essen Biotech and currently in Phase II for Metastatic Breast Cancer.

New research reveals that ER+ breast cancer cells acquire aggressive characteristics through direct contact with bone marrow ...

Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Gastric Cancer.

Dosing Schedule for Adjuvant Chemo in High-Risk Early Breast Cancer Can Be Patient’s Choice ...

An expanding body of research indicates that aerobic exercise and strength-training can improve the chances of survival.

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...